JNJ

#20
Johnson & Johnson Common Stock
227.8 1 USD
-1.33%
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
227.72
231.48
Yıllık Aralık
149.04
251.71
Günlük Değişim
-1.33%
Aylık Değişim
-0.05%
6 Aylık Değişim
+10.45%
Yıllık Değişim
+48.02%
Önceki Kapanış
230.8 7
Open
230.8 8
Düşük
227.7 2
High
231.4 8
Hacim
682
Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler Temettüler
Çeyreklik Yıllık
  • Market Capitalization 548.39 B
  • Employee 141 K
  • Founded N/A
  • CEO Joaquin Duato
  • Website www.jnj.com
  • Headquarter New Jersey, United States
  • FIGI BBG000BMHYD1
  • Industry İlaç Üreticileri - Genel
Toplam gelir
Net kar
Temel hisse başına kazanç (Temel EPS)
Toplam borç
Serbest nakit akışı
Nakit ve eşdeğerleri
Fiyat/kazanç oranı
18.82
Fiyat/satışlar oranı
5.35
Hisse başına temettü
5.14
Temettü getirisi %
2.48

Johnson & Johnson Common Stock

Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company operates 2 divisions: Innovative Medicine and MedTech. Major products produced by the Innovative Medicine division are CARVYKTI for multiple myeloma; DARZALEX, also for multiple myeloma; ERLEADA, for prostate cancer; REMICADE, for inflammatory diseases; SIMPONI/SIMPONI ARIA, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis; STELARA, for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; TREMFYA, for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis; INVEGA SUSTENNA/XEPLION, for schizophrenia; SPRAVATO, a nasal spray for depression; OPSUMIT /OPSYNVI for pulmonary arterial hypertension; and UPTRAVI for pulmonary arterial hypertension. The MedTech division produces products used for cardiovascular, orthopaedics, surgery, and vision treatments. The company is ranked 48th on the Fortune 500 and 42nd on the Forbes Global 2000.

Haberler